|
Relistor CRL May Trigger More Safety Concerns With Constipation Drugs
The FDA’s recent complete response letter (CRL) on Salix’s sNDA for opioid-induced constipation (OIC) drug Relistor most likely cites safety concerns and signals increased scrutiny for all makers of these drugs, analysts say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives